Palbociclib CDK (cyclin-dependent kinase) inhibitor

PD-0332991 - PD0332991 - PD 0332991 - Ibrance - palbociclib



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - CDK (cyclin-dependent kinase) inhibitor in all type of patients - CDK (cyclin-dependent kinase) inhibitor in HR+ HER2-

PENELOPE-B ongoing palbociclibplaceboNA Confirmatory NCT01864746
PALOMA-4 ongoing palbociclib + letrozoleletrozole aloneNA Confirmatory NCT02297438
PEARL ongoing palbociclib + exemestanecapecitabineNA Confirmatory - NCT02028507
PALOMA 3, 2015palbociclib + fulvestrantfulvestrant alone2nd line521 (347/174) Confirmatory NCT01942135
PALOMA-2, 2016palbociclib + letrozoleletrozole alonefirst line666 Confirmatory NCT01740427
PALOMA 1/TRIO-18, 2015palbociclib + letrozoleletrozole alone165 (84/81) Exploratory NCT00721409